The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Qadan M (1), Kothary N (2), Sangro B (3), Palta M (4).
(1) Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
(2) Department of Radiology, Stanford University Medical Center, Palo Alto, CA.
(3) Department of Medicine, Clinica Universidad de Navarra, Pamplona, Spain.
(4) Department of Radiation Oncology, Duke University, Durham, NC.
Hepatocellular carcinoma (HCC) is the sixth most common cancer and third leading cause of cancer-related death worldwide. HCC is also is a tumor with a distinct ability to invade and grow within the hepatic vasculature.
Approximately 20% of patients with HCC have macrovascular invasion (MVI) at the time of diagnosis. MVI is associated with dismal prognosis, with median survival ranging from 2 to 5 months. Current staging systems designate MVI as advanced disease.
Recent advances in multimodal approaches, including systemic therapies, radiation therapy, liver-directed therapies, and surgical approaches, in the treatment of HCC with MVI have rendered this disease process more treatable with improved outcomes and are discussed here.
CITA DEL ARTÍCULO Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-8. doi: 10.1200/EDBK_280811